In this pipeline report, Dermatology Times presents insights into Hh pathway inhibitors currently in phase 2 and phase 3 for the treatment of basal cell carcinoma.
Stephen Huber
Advertisement
Articles by Stephen Huber
Innovative melanoma therapeutics are on the horizon. This pipeline report highlights some of the new drugs currently in phase 2, phase 3 or recently approved for the treatment of melanoma.
Advertisement
Latest Updated Articles
Basal cell carcinoma treatments on the horizonPublished: June 13th 2019 | Updated:
What's new in melanoma treatment?Published: June 13th 2019 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
4
Dermatology Conferences and Meetings Calendar: December 2025
5
